{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:44:53Z","timestamp":1786373093444,"version":"build-2736575974"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["33IC30_166785\/1"],"award-info":[{"award-number":["33IC30_166785\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["NCCR TransCure"],"award-info":[{"award-number":["NCCR TransCure"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["NCCR Kidney.CH"],"award-info":[{"award-number":["NCCR Kidney.CH"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Nephrolithiasis is a common health problem in autosomal dominant polycystic kidney disease (ADPKD) and significantly contributes to patient morbidity. Recently, Tolvaptan has been introduced for the treatment of ADPKD, but whether it is associated with alterations of the urinary lithogenic risk profile remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>We conducted an analysis of participants enrolled in the Bern ADPKD registry, a prospective observational cohort study. Twenty-four-hour urine analyses were performed at baseline and then at yearly follow-ups. Relative supersaturation ratios for calcium oxalate, brushite, and uric acid were calculated with the program EQUIL2. Unadjusted and multivariable mixed-effects linear regression models, adjusted for age, sex, body mass index, eGFR, net acid excretion, and height-adjusted total kidney volume, were used to assess the association of Tolvaptan with urinary parameters relevant for kidney stone formation. The maximum individual follow-up time was 3 years, median follow-up time 1.9 years, and cumulative follow-up time 169 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 125 participants (38 with and 87 without Tolvaptan treatment) were included in the analysis. In multivariable analysis, Tolvaptan treatment was associated [adjusted estimate of the difference between Tolvaptan and no Tolvaptan; 95% confidence interval (CI)] with lower urine relative supersaturation ratios for calcium oxalate (\u22120.56; 95% CI, \u22120.82 to \u22120.3;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), brushite (\u22120.33; 95% CI, \u22120.54 to \u22120.11;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.004), and uric acid (\u22120.62; 95% CI, \u22120.88 to \u22120.37;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), and with higher urine citrate in mmol\/mmol creatinine per day (0.25; 95% CI, 0.05 to 0.46;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.02) and calcium in mmol\/mmol creatinine per day (0.31; 95% CI, 0.09 to 0.53;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.006) excretion. In addition, Tolvaptan treatment was associated with lower net acid excretion in mEq\/mmol creatinine per day (\u22120.54; 95% CI, \u22120.90 to \u22120.17;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.004) and higher net gastrointestinal alkali absorption in mEq\/mmol creatinine per day (0.57; 95% CI, 0.26 to 0.88;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tolvaptan treatment is associated with a significantly improved urinary lithogenic risk profile in patients with ADPKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.13861119","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T15:26:55Z","timestamp":1591889215000},"page":"1007-1014","source":"Crossref","is-referenced-by-count":33,"title":["Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan"],"prefix":"10.2215","volume":"15","author":[{"given":"Matteo","family":"Bargagli","sequence":"first","affiliation":[{"name":"U.O.C. Nefrologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy"},{"name":"Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser A.","family":"Dhayat","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Anderegg","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Semmo","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uyen","family":"Huynh-Do","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vogt","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-022X","authenticated-orcid":false,"given":"Pietro Manuel","family":"Ferraro","sequence":"additional","affiliation":[{"name":"U.O.C. Nefrologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy"},{"name":"Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-1803","authenticated-orcid":false,"given":"Daniel G.","family":"Fuster","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.ajkd.2014.05.020","article-title":"ESRD from autosomal dominant polycystic kidney disease in the United States, 2001-2010","volume":"64","author":"Reule","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/ckj\/sfz011","article-title":"The European renal association - European dialysis and transplant association (ERA-EDTA) registry annual report 2016: A summary","volume":"12","author":"Kramer","year":"2019","journal-title":"Clin Kidney J"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Mutations in GANAB, encoding the glucosidase II\u03b1 subunit, cause autosomal-dominant polycystic kidney and liver disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am J Hum Genet"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2015.59","article-title":"Autosomal-dominant polycystic kidney disease (ADPKD): Executive summary from a kidney disease: Improving global outcomes (KDIGO) controversies conference","volume":"88","author":"Chapman","year":"2015","journal-title":"Kidney Int"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2017050483","article-title":"Genetic complexity of autosomal dominant polycystic kidney and liver diseases","volume":"29","author":"Cornec-Le Gall","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"838","DOI":"10.2215\/CJN.03100608","article-title":"Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients","volume":"4","author":"Nishiura","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2214\/ajr.159.1.1609726","article-title":"Calcified renal stones and cyst calcifications in autosomal dominant polycystic kidney disease: Clinical and CT study in 84 patients","volume":"159","author":"Levine","year":"1992","journal-title":"AJR Am J Roentgenol"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0272-6386(88)80137-9","article-title":"The association of nephrolithiasis and autosomal dominant polycystic kidney disease","volume":"11","author":"Torres","year":"1988","journal-title":"Am J Kidney Dis"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00240-005-0019-z","article-title":"Lithiasis in cystic kidney disease and malformations of the urinary tract","volume":"34","author":"Gambaro","year":"2006","journal-title":"Urol Res"},{"key":"B10-20230813","first-page":"1320","article-title":"[Urinary stones and urinary tract abnormalities: Is the stone composition independent of the anatomical abnormality?]","volume":"13","author":"Daudon","year":"2003","journal-title":"Prog Urol"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1038\/ki.1994.227","article-title":"Renal ammonia in autosomal dominant polycystic kidney disease","volume":"45","author":"Torres","year":"1994","journal-title":"Kidney Int"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/ajkd.2000.8266","article-title":"Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease","volume":"36","author":"Grampsas","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.juro.2015.11.027","article-title":"Short-term tolvaptan increases water intake and effectively decreases urinary calcium oxalate, calcium phosphate and uric acid supersaturations","volume":"195","author":"Cheungpasitporn","year":"2016","journal-title":"J Urol"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","article-title":"Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1","volume":"343","author":"Ravine","year":"1994","journal-title":"Lancet"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: A new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/S0022-5347(17)47703-2","article-title":"EQUIL2: A BASIC computer program for the calculation of urinary saturation","volume":"134","author":"Werness","year":"1985","journal-title":"J Urol"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/ki.1993.221","article-title":"Calculation of titratable acidity from urinary stone risk factors","volume":"44","author":"Kok","year":"1993","journal-title":"Kidney Int"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1681\/ASN.V11112155","article-title":"Endogenous production of fixed acid and the measurement of the net balance of acid in normal subjects","volume":"11","author":"Relman","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate [published correction appears in Ann Intern Med 155: 408, 2011]","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/qjmed\/hcu251","article-title":"A London experience 1995-2012: Demographic, dietary and biochemical characteristics of a large adult cohort of patients with renal stone disease","volume":"108","author":"Ferraro","year":"2015","journal-title":"QJM"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0272-6386(12)80922-X","article-title":"Renal stone disease in autosomal dominant polycystic kidney disease","volume":"22","author":"Torres","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/j.ajkd.2016.08.028","article-title":"Tolvaptan and kidney pain in patients with autosomal dominant polycystic kidney disease: Secondary analysis from a randomized controlled trial","volume":"69","author":"Casteleijn","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.juro.2018.06.029","article-title":"Short-term changes in urinary relative supersaturation predict recurrence of kidney stones: A tool to guide preventive measures in urolithiasis","volume":"200","author":"Ferraro","year":"2018","journal-title":"J Urol"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0022-5347(01)66321-3","article-title":"Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: A 5-year randomized prospective study","volume":"155","author":"Borghi","year":"1996","journal-title":"J Urol"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/ki.1997.126","article-title":"Correspondence between stone composition and urine supersaturation in nephrolithiasis","volume":"51","author":"Parks","year":"1997","journal-title":"Kidney Int"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJMoa010369","article-title":"Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria","volume":"346","author":"Borghi","year":"2002","journal-title":"N Engl J Med"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1172\/JCI105466","article-title":"The effects of diet and stool composition on the net external acid balance of normal subjects","volume":"45","author":"Lennon","year":"1966","journal-title":"J Clin Invest"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"18644","DOI":"10.1073\/pnas.1318257110","article-title":"Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia","volume":"110","author":"Tamma","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1681\/ASN.2018080816","article-title":"Vasopressin increases urinary acidification via V1a receptors in collecting duct intercalated cells","volume":"30","author":"Giesecke","year":"2019","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.13861119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:15Z","timestamp":1786369335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.13861119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.13861119","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]}}}